Chonghelin is a high-quality human insulin produced by Bayer Healthcare Co., Ltd. Production is completely carried out under the world's most stringent pharmaceutical production and quality management system - EU GMP standards; Zhonghelin's production process has two patents from 58 countries including the United States, the European Union, China, etc. (the production process Patent, patent for carboxypeptidase B).
Compared with other human insulins, Zhonghelin not only ensures high-quality efficacy, but also has a price advantage, reducing the financial burden on patients. After the listing of Zhonghelin, Bayer Healthcare has a complete diabetes management program in China that includes oral diabetes treatment drugs, insulin products, blood glucose monitoring instruments, and diabetes education.